Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms

• Kaitlyn Shank,
• Andrew Dunbar,
• Priya Koppikar,
• Maria Kleppe,
• Julie Teruya-Feldstein,
• Isabelle Csete,
• Neha Bhagwat,
• Matthew Keller,
• Outi Kilpivaara,
• Franziska Michor,
• Ross L. Levine,
• Laura de Vargas Roditi

Affiliations

Kaitlyn Shank

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA;Penn State College of Medicine, Hershey, Pennsylvania, USA

Andrew Dunbar

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Priya Koppikar

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Maria Kleppe

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Julie Teruya-Feldstein

Department of Pathology, Icahn School of Medicine, Mount Sinai, New York, NY, USA

Isabelle Csete

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Neha Bhagwat

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA;Gerstner Sloan-Kettering Graduate School in Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Matthew Keller

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Outi Kilpivaara

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Franziska Michor

Department of Biostatistics and Computational Biology, Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA;Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA;Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA

Ross L. Levine

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA;Gerstner Sloan-Kettering Graduate School in Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA;Leukemia Service, Memorial Sloan-Kettering Cancer Center, NY, USA

Laura de Vargas Roditi

Institute of Molecular Cancer Research, University of Zurich, Zurich Switzerland